Nyrada Inc
Nyrada Inc. is an Australia-based biotechnology company. The Company is focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The Company’…
The business
Nyrada Inc. is an Australia-based biotechnology company. The Company is focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The Company’s lead candidate, Xolatryp, is a small molecule cardio protection and neuroprotection therapy. Xolatryp has demonstrated preclinical efficacy as an acute treatment following ischemic stroke, traumatic brain injury (TBI), and acute myocardial infarction (AMI). Xolatryp, is also a novel blocker targeting TRPC 3/6/7 ion channels, developed to mitigate secondary brain injury and prevent further brain cell death. The critical role of TRPC 3/6/7 channels in secondary injury has been validated in animal knockout models and through research-grade blockers. Its medical programs include Myocardial Ischemia and Arrhythmia Control, Stroke, and Traumatic Brain Injury.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Nyrada Announces Preclinical Oncology Efficacy for Xolatryp and US Patent Allowance
Nyrada reports strong preclinical Xolatryp efficacy in liver cancer and a US patent allowance, highlighting a ~39% boost vs doxorubicin alone.
Nyrada Confirms Xolatryp Offers Mitochondrial Stabilisation after Traumatic Brain Injury
Nyrada (ASX: NYR) has confirmed its small molecule therapy Xolatryp can reduce mitochondrial calcium ion loading in the brain following traumatic injury. A collaborative study with the University of New South Wales and the Walter Reed Army Institute of Research sought to evaluate the efficacy of Xolatryp in a penetrating traumatic brain injury (TBI) rodent […]
Weekly wrap: rumours of wars send the ASX 200 tumbling
It is the Bible that talks about not being alarmed by “wars and rumours of wars” but Australian share market investors weren’t quite so sanguine, pushing down the ASX 200 sharply. By the close of trade on Friday 55.2 points or 0.7% had been erased from the ASX 200 as the reality of a worsening […]
Nyrada’s NYR-BI03 shows significant cardioprotective efficacy in preclinical study
A preclinical rat study using Nyrada’s (ASX: NYR) lead drug candidate NYR-BI03 has demonstrated up to 86% efficacy in limiting cardiovascular damage associated with coronary heart disease following acute myocardial ischaemic-reperfusion injury. The findings are believed to position NYR-BI03 as a novel cardioprotective treatment following myocardial infarction, which is a leading cause of morbidity and […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.